Table 1.
Data for Patients Overall and Matched Patients after Propensity Scoring
| Overall Patients | Matched Patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | TIVA (n = 903) | VIA (n = 1304) | ASD | P | TIVA (n = 729) | VIA (n = 729) | ASD | P |
| Age, yr | 58.0 [49.0;67.0] | 57.0 [48.0;67.0] | 0.098 | 0.018 | 58.0 [49.0;67.0] | 57.0 [48.0;67.0] | 0.003 | 0.861 |
| Sex | 0.233 | < 0.001 | 0.019 | 0.753 | ||||
| Female | 404 (44.7%) | 734 (56.3%) | 337 (46.2%) | 344 (47.2%) | ||||
| Male | 499 (55.3%) | 570 (43.7%) | 392 (53.8%) | 385 (52.8%) | ||||
| Height, cm | 161.0 [154.0;166.0] | 159.0 [154.0;165.0] | 0.118 | 0.007 | 161.0 [154.0;166.0] | 161.0 [155.0;166.0] | 0.015 | 0.610 |
| Weight, kg | 60.0 [54.0;67.0] | 60.0 [54.0;67.0] | 0.002 | 0.368 | 60.0 [54.0;67.0] | 60.0 [53.0;67.0] | 0.023 | 0.527 |
| BMI, kg m−2 | 23.6 [21.8;25.8] | 23.8 [21.8;26.1] | 0.062 | 0.210 | 23.6 [21.7;25.8] | 23.5 [21.5;25.8] | 0.039 | 0.577 |
| ASA class | 0.098 | 0.067 | 0.053 | 0.605 | ||||
| I | 399 (44.2%) | 633 (48.5%) | 311 (42.7%) | 310 (42.5%) | ||||
| II | 503 (55.7%) | 671 (51.5%) | 417 (57.2%) | 419 (57.5%) | ||||
| III | 1 (0.1%) | 0 (0.0%) | 1 (0.1%) | 0 (0.0%) | ||||
| Hypertension | 0.008 | 0.894 | < 0.001 | 1.000 | ||||
| Yes | 233 (25.8%) | 341 (26.2%) | 188 (25.8%) | 188 (25.8%) | ||||
| No | 670 (74.2%) | 963 (73.8%) | 541 (74.2%) | 541 (74.2%) | ||||
| DM | 0.057 | 0.204 | 0.032 | 0.593 | ||||
| Yes | 121 (13.4%) | 150 (11.5%) | 95 (13.0%) | 103 (14.1%) | ||||
| No | 782 (86.6%) | 1154 (88.5%) | 634 (87.0%) | 626 (85.9%) | ||||
| Anesthesia time, min | 230.0 [185.0;285.0] | 210.0 [170.0;260.0] | 0.166 | < 0.001 | 215.0 [180.0;260.0] | 220.0 [180.0;265.0] | 0.017 | 0.696 |
| Operation time, min | 190.0 [150.0;240.0] | 175.0 [135.0;220.0] | 0.146 | < 0.001 | 180.0 [149.0;220.0] | 180.0 [149.0;225.0] | 0.012 | 0.787 |
| Remifentanil infusion | < 0.001 | < 0.001 | ||||||
| Yes | 902 (99.9%) | 701 (53.8%) | 728 (99.9%) | 395 (54.2%) | ||||
| No | 1 (0.1%) | 603 (46.2%) | 1 (0.1%) | 334 (45.8%) | ||||
| Gas type | < 0.001 | < 0.001 | ||||||
| Des | 0 (0.0%) | 345 (26.5%) | 0 (0.0%) | 193 (26.5%) | ||||
| Iso | 0 (0.0%) | 31 (2.4%) | 0 (0.0%) | 25 (3.5%) | ||||
| Sevo | 0 (0.0%) | 927 (71.1%) | 0 (0.0%) | 511 (70%) | ||||
| Nitrous oxide | < 0.001 | < 0.001 | ||||||
| Yes | 1 (0.1%) | 550 (42.2%) | 1 (0.1%) | 302 (41.4%) | ||||
| No | 902 (99.9%) | 754 (57.8%) | 728 (99.9%) | 427 (58.6%) | ||||
| Metastasis at surgery | 0.006 | 0.947 | 0.014 | 0.855 | ||||
| Yes | 68 (7.5%) | 96 (7.4%) | 64 (8.8%) | 67 (9.2%) | ||||
| No | 835 (92.5%) | 1208 (92.6%) | 665 (91.2%) | 662 (90.8%) | ||||
| Transfusion | 0.056 | 0.252 | 0.038 | 0.626 | ||||
| Yes | 19 (2.1%) | 39 (3.0%) | 10 (1.4%) | 7 (1.0%) | ||||
| No | 884 (97.9%) | 1265 (97.0%) | 719 (98.6%) | 722 (99.0%) | ||||
| Hospital stay, day | 13.0 [11.0;18.0] | 13.0 [10.0;18.0] | 0.014 | 0.238 | 13.0 [11.0;18.0] | 13.0 [10.0;18.0] | 0.023 | 0.355 |
| Survival, month | 60.0 [44.0;60.0] | 60.0 [45.0;60.0] | 0.945 | 60.0 [40.0;60.0] | 60.0 [47.0;60.0] | 0.523 | ||
| 5 years survival | 0.291 | 0.262 | ||||||
| Yes | 829 (91.8%) | 1214 (93.1%) | 660 (90.5%) | 673 (92.3%) | ||||
| No | 74 (8.2%) | 90 (6.9%) | 69 (9.5%) | 56 (7.7%) | ||||
| Cancer type | < 0.001 | 1.000 | ||||||
| Breast | 154 (17.1%) | 475 (36.4%) | 154 (21.1%) | 154 (21.1%) | ||||
| Colon | 362 (40.1%) | 188 (14.4%) | 188 (25.8%) | 188 (25.8%) | ||||
| Liver | 37 (4.1%) | 90 (6.9%) | 37 (5.1%) | 37 (5.1%) | ||||
| Lung | 44 (4.9%) | 103 (7.9%) | 44 (6.0%) | 44 (6.0%) | ||||
| Stomach | 306 (33.9%) | 448 (34.4%) | 306 (42.0%) | 306 (42.0%) | ||||
Number (%): chi-square test, median [interquartile range]: Mann–Whitney U test
ASD Absolute standardized mean difference, BMI Body mass index, ASA American Society of Anesthesiologists, TIVA Total intravenous anesthesia, VIA Volatile inhalational anesthesia, DM Diabetes mellitus, Des Desflurane, Iso Isoflurane, Sevo Sevoflurane